Sai Life Sciences (SAILIFE) Q2 25/26 earnings summary

Executive summary

• Delivered a strong Q2 FY26 with robust demand and momentum across discovery, development, and manufacturing services, driven by global client trust, scientific execution, and expanding client relationships.

• Growth strategy anchored on scientific depth, technological differentiation, global scale, and responsible scaling, with a focus on being a strategic partner for clients and deepening collaborations.

• Successfully offset biotech funding slowdown with increased engagement from large pharma clients and a robust, diversified client base.

• Expanded capabilities in peptides, flow chemistry, ADCs, bioconjugates, and completed phase two expansion of Hyderabad R&D Center.

• Entered the animal health segment with a dedicated veterinary API facility and partnerships with top global animal health companies.

Financial highlights

• H1 FY26 total revenue reached ₹1,034 crore, up 53% year-over-year from ₹675 crore in H1 FY25; Q2 FY26 revenue was ₹537.47 crore, up 36% year-over-year.

• CDMO business contributed 64–66% of revenue, up 72% year-over-year; CRO business contributed 34–36%, up 28% year-over-year.

• EBITDA for H1 FY26 was ₹281 crore, a 101% increase from H1 FY25; EBITDA margin improved to 27.2%, up 652 bps year-over-year.

• PAT for Q2 FY26 stood at ₹84 crore, up 102% year-over-year; H1 FY26 PAT was ₹144 crore.

• CapEx for H1 FY26 was ₹248 crore, with a full-year plan of ₹700 crore focused on R&D and new technologies.

Outlook and guidance

• Capacity expansion on track to increase installed capacity from 700 KL to 1,150 KL by end of FY27.

• Confident in achieving 15–20% revenue CAGR over a three to five year period and 28–30% EBITDA margins in the next 2–3 years.

• Focus remains on improving asset productivity, optimizing working capital, and strengthening margin profile.

• Management and auditors confirm compliance with accounting standards and regulatory requirements, with no material misstatements identified.